{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:51:23Z","timestamp":1771667483669,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen kanker","doi-asserted-by":"publisher","award":["0010091"],"award-info":[{"award-number":["0010091"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.euf.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T23:39:09Z","timestamp":1739921949000},"page":"595-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial\u2014Results of Secondary Endpoints"],"prefix":"10.1016","volume":"11","author":[{"given":"Flor","family":"Verghote","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Rammant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Dirix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlien","family":"Berghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Junius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Liefhooghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen","family":"No\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Decaestecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Villeirs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Decruyenaere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathia","family":"De Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"De Maeseneer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.02.005_b0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ijrobp.2012.03.061","article-title":"Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy","volume":"85","author":"Baumann","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.02.005_b0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.28544","article-title":"Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710","volume":"120","author":"Christodouleas","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.02.005_b0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jjco\/hyn036","article-title":"The predictors of local recurrence after radical cystectomy in patients with invasive bladder cancer","volume":"38","author":"Ide","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0020","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.005_b0025","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0030","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.005_b0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.02.005_b0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0360-3016(92)91060-Z","article-title":"Combined pre- and postoperative adjuvant radiation therapy for bladder cancer\u2014a ten year experience","volume":"24","author":"Reisinger","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.02.005_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2017.4591","article-title":"Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy a randomized phase 2 trial","volume":"153","author":"Zaghloul","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.euf.2025.02.005_b0050","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ijrobp.2024.05.012","article-title":"The value and safety of adjuvant radiation therapy after radical cystectomy in locally advanced urothelial bladder cancer: a controlled randomized study","volume":"120","author":"Zaghloul","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.02.005_b0055","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.euf.2021.11.004","article-title":"Adjuvant radiotherapy after radical cystectomy for patients with high-risk muscle-invasive bladder cancer: results of a multicentric phase II trial","volume":"8","author":"Fonteyne","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.02.005_b0060","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12885-017-3302-9","article-title":"Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial","volume":"17","author":"Fonteyne","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2025.02.005_b0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.02.005_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12955-022-02064-z","article-title":"Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer","volume":"20","author":"Ripping","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.euf.2025.02.005_b0075","unstructured":"NIH. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). https:\/\/ctep.cancer.gov."},{"key":"10.1016\/j.euf.2025.02.005_b0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.prro.2022.05.014","article-title":"International consensus guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy: update from an IBIS workgroup","volume":"12","author":"Verghote","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.urolonc.2011.01.008","article-title":"A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer","volume":"31","author":"El-Monim","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.01.015","article-title":"Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy","volume":"39","author":"Murthy","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0095","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2024.09.040","article-title":"Bladder adjuvant radiation therapy (BART): acute and late toxicity from a phase III multicenter randomized controlled trial","volume":"121","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.euf.2025.02.005_b0100","unstructured":"Flaig TW, Spiess PE, Abern M, et al. NCCN guidelines: bladder cancer. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.euf.2025.02.005_b0105","unstructured":"Witjes JA, Bruins HM, Carri\u00f3n A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer."},{"key":"10.1016\/j.euf.2025.02.005_b0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0115","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","article-title":"Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.02.005_b0120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2009.11.040","article-title":"Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging","volume":"79","author":"Hayman","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.02.005_b0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.adro.2019.01.005","article-title":"Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer","volume":"4","author":"Schad","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0130","doi-asserted-by":"crossref","first-page":"S590","DOI":"10.1016\/j.annonc.2020.08.837","article-title":"765P: Predicting survival in urothelial cancer patients after immunotherapy using real-world data","volume":"31","author":"Elumalai","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.02.005_b0135","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.clon.2023.04.010","article-title":"Study protocol of the Bladder Adjuvant RadioTherapy (BART) trial: a randomised phase III trial of adjuvant radiotherapy following cystectomy in bladder cancer","volume":"35","author":"Murthy","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:50:05Z","timestamp":1768956605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2405456925000422"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Radiotherapy After Radical Cystectomy for Muscle-invasive Bladder Cancer: A Phase 2 Trial\u2014Results of Secondary Endpoints","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}